WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Current US FDA-cleared stool-based colorectal cancer (CRC) molecular screening tests include fecal immunochemical tests (FIT) for occult blood detection; however, integration with nucleic acid-based ...

IDEXX Laboratories, Inc. IDXX recently expanded its Fecal Dx antigen testing platform with the addition of Cystoisospora — a common intestinal parasite that is the source of diarrhea, weight loss and ...

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...

Routine screening with fecal occult blood testing (FOBT) is associated with a decrease in colorectal cancer (CRC) mortality, according to a study published online Feb. 27 in JAMA Network Open.

Large, prospective cohorts are needed to research the gut microbiome’s role in colorectal cancer (CRC) risk. We evaluated the gut microbiome leveraging residual fecal immunochemical tests (FIT) from a ...

Everyone's mailing in stool samples for a gut report, but can an at-home microbiome test actually tell you anything?

Stool-based tests for colorectal cancer (CRC) screening show no significant difference in detecting advanced neoplasia overall, but for advanced serrated lesions specifically, the multitarget stool ...